Efficacy and safety of semaglutide in patients with heart failure with preserved ejection fraction and obesity
Clinical Cardiology · 2024
DOI: 10.1002/clc.24283 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Cardiology, 2024. Verfasst von Ayesha Rehman und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Quaid e Azam Medical College, Bahawalpur, Pakistan. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Heart Failure, Stroke Volume, Obesity. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
Semaglutide, a once‐weekly glucagon‐like peptide‐1 receptor agonist, has shown promise in weight management and cardiovascular outcomes in other populations. This study aimed to evaluate the efficacy of semaglutide in heart failure with preserved ejection fraction (HFpEF) patients with obesity.
Methods
A retrospective study analyzed 318 patients with HFpEF, of which 104 received semaglutide and 214 received placebo. Primary endpoints included evaluating changes in exercise capacity and weight management.
Results
Semaglutide treatment led to significant improvements in the primary endpoints. Patients in the semaglutide group demonstrated substantial enhancements in exercise capacity, as measured by the 6‐min walk distance, compared to the placebo group (mean difference 15.1 meters, 95% CI 5.8 to 24.4, p = 0.002). Additionally, semaglutide resulted in substantial weight loss compared to placebo (mean difference −2.9%, 95% CI −4.1–−1.7, p = 0.001). Several secondary endpoints, including reductions in C‐reactive protein levels and improvements in other clinical parameters, further supported the efficacy of semaglutide. Adverse events were generally well‐tolerated, with no unexpected safety concerns.
Conclusion
Semaglutide demonstrated significant clinical benefits in HFpEF patients with obesity, as evidenced by improved symptoms, physical function, and weight reduction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Quaid e Azam Medical College, Bahawalpur, Pakistan.
- Department of Cardiology, Pakistan Institute of Medical Sciences, Islamabad, Pakistan.
- Department of Cardiology, Benazir Bhutto Hospital, Rawalpindi, Pakistan.
- Department of Medicine, Reading Hospital, West Reading, PA, USA.
- Department of Medicine, Military Hospital, Rawalpindi, Pakistan.
- Department of Medicine, Ayub Teaching Hospital, Abbottabad, Pakistan.
Zitieren
APA
Rehman, A., Saidullah, S., Asad, M., Gondal, U. R., Ashraf, A., Khan, M. F., Akhtar, W., Mehmoodi, A., & Malik, J. (2024). Efficacy and safety of semaglutide in patients with heart failure with preserved ejection fraction and obesity. Clinical Cardiology. https://doi.org/10.1002/clc.24283
Vancouver
Rehman A, Saidullah S, Asad M, Gondal UR, Ashraf A, Khan MF, et al. Efficacy and safety of semaglutide in patients with heart failure with preserved ejection fraction and obesity. Clinical Cardiology. 2024. doi:10.1002/clc.24283
BibTeX
@article{Rehman2024,
author = {Rehman, Ayesha and Saidullah, Shahab and Asad, Muhammad and Gondal, Umer R and Ashraf, Amna and Khan, Muhammad F and Akhtar, Waheed and Mehmoodi, Amin and Malik, Jahanzeb},
title = {Efficacy and safety of semaglutide in patients with heart failure with preserved ejection fraction and obesity},
journal = {Clinical Cardiology},
year = {2024},
doi = {10.1002/clc.24283}
}
EUVIMED